The pharmacological mechanism of tirzepatide produces significant clinical benefits including improved glycemic control, substantial weight reduction (typically 5-20% of body weight in clinical trials, varying by dose and population), and favorable effects on cardiovascular risk factors
Nat Rev Endocrinol 8:728742 Mentzer RM Jr, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, EXPEDITION Study Investigators et al (2008) Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study
PubMed lists well over 100 studies, and the number of annual publications has grown quickly from about 45 results in 2020 to more than 180 in 2025 yet there are still no completed Phase III human trials
generated mice with L cells expressing GFP
[1] It is not indicated for type 1 diabetes, diabetic ketoacidosis, or for use in patients under 18 years of age
For instance, ROS may have played a key role in drug-induced retinopathy (such as the antimalarial drug chloroquine and the antibiotic gentamicin)